Equities Analysts Offer Predictions for TVTX FY2027 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities research analysts at HC Wainwright upped their FY2027 EPS estimates for Travere Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $2.55 for the year, up from their previous forecast of $0.95. HC Wainwright currently has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics’ FY2028 earnings at $4.67 EPS and FY2029 earnings at $5.70 EPS.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. The company had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same period in the prior year, the business posted ($0.70) earnings per share. The firm’s revenue for the quarter was up 162.1% compared to the same quarter last year.

A number of other analysts also recently commented on the company. Piper Sandler boosted their target price on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Scotiabank reiterated an “outperform” rating on shares of Travere Therapeutics in a research report on Thursday, August 7th. Wedbush increased their target price on Travere Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Finally, Citigroup upped their price objective on Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average price target of $38.71.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $33.89 on Wednesday. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -16.61 and a beta of 0.90. The company has a debt-to-equity ratio of 9.50, a current ratio of 2.00 and a quick ratio of 1.98. The business’s 50 day simple moving average is $27.40 and its 200-day simple moving average is $20.50. Travere Therapeutics has a 12 month low of $12.91 and a 12 month high of $36.76.

Institutional Investors Weigh In On Travere Therapeutics

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new stake in Travere Therapeutics during the 2nd quarter worth $33,000. First Horizon Corp purchased a new position in Travere Therapeutics in the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Travere Therapeutics during the first quarter valued at approximately $62,000. Headlands Technologies LLC purchased a new position in shares of Travere Therapeutics in the second quarter valued at $73,000. Finally, Atria Investments Inc acquired a new stake in Travere Therapeutics during the 2nd quarter valued at $154,000.

Insider Activity at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 10,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider directly owned 89,878 shares in the company, valued at $2,246,950. This represents a 10.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Sandra Calvin sold 67,115 shares of Travere Therapeutics stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer owned 48,545 shares in the company, valued at $1,747,620. The trade was a 58.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 223,941 shares of company stock worth $7,221,380. 4.19% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.